Literature DB >> 23666548

Nervous system lyme disease: diagnosis and treatment.

John J Halperin1.   

Abstract

OPINION STATEMENT: The tick-borne spirochete responsible for Lyme disease is highly antibiotic-sensitive. Treatment related misconceptions can be attributed to confusion in three principal realms: (1) the appropriate approach to diagnosis (who should be treated); (2) necessary and appropriate treatment; and (3) what actually constitutes nervous system infection and to what extent this mandates different treatment. Contrary to often-repeated assertions, laboratory-based diagnosis-in the appropriate setting-is as valid as it is in most other serologically diagnosed infections. Treatment is highly effective in the vast majority of patients, including those with nervous system disease. Nervous system infection, most typically meningitis, cranial neuritis, radiculoneuritis, and other forms of mononeuropathy multiplex, is highly antibiotic responsive. The encephalopathy that can be seen in some patients with active infection represents the same phenomenon that occurs in patients with many other inflammatory disorders, is not evidence of central nervous system (CNS) infection, and does not require any different, more prolonged, or more intensive treatment. In patients with infection not involving the CNS, oral treatment with amoxicillin, cefuroxime axetil, or doxycycline for 2-4 weeks is almost always curative. Despite historic preferences for parenteral treatment with ceftriaxone, cefotaxime, or meningeal dose penicillin, patients with the forms of nervous system involvement listed above are highly responsive to oral doxycycline. Parenteral regimens can be reserved for those very rare patients with parenchymal CNS involvement, other severe forms of infection, or the approximately 5 % of patients who fail to respond to oral regimens.

Entities:  

Year:  2013        PMID: 23666548     DOI: 10.1007/s11940-013-0240-y

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  30 in total

1.  Spirochete antigens persist near cartilage after murine Lyme borreliosis therapy.

Authors:  Linda K Bockenstedt; David G Gonzalez; Ann M Haberman; Alexia A Belperron
Journal:  J Clin Invest       Date:  2012-06-25       Impact factor: 14.808

2.  Musculoskeletal and neurologic outcomes in patients with previously treated Lyme disease.

Authors:  N A Shadick; C B Phillips; O Sangha; E L Logigian; R F Kaplan; E A Wright; A H Fossel; K Fossel; V Berardi; R A Lew; M H Liang
Journal:  Ann Intern Med       Date:  1999-12-21       Impact factor: 25.391

3.  Erythema chronicum migrans and Lyme arthritis. The enlarging clinical spectrum.

Authors:  A C Steere; S E Malawista; J A Hardin; S Ruddy; W Askenase; W A Andiman
Journal:  Ann Intern Med       Date:  1977-06       Impact factor: 25.391

4.  Long-term outcomes of persons with Lyme disease.

Authors:  E G Seltzer; M A Gerber; M L Cartter; K Freudigman; E D Shapiro
Journal:  JAMA       Date:  2000-02-02       Impact factor: 56.272

5.  Lyme neuroborreliosis. Peripheral nervous system manifestations.

Authors:  J Halperin; B J Luft; D J Volkman; R J Dattwyler
Journal:  Brain       Date:  1990-08       Impact factor: 13.501

6.  Single-tier testing with the C6 peptide ELISA kit compared with two-tier testing for Lyme disease.

Authors:  Gary P Wormser; Martin Schriefer; Maria E Aguero-Rosenfeld; Andrew Levin; Allen C Steere; Robert B Nadelman; John Nowakowski; Adriana Marques; Barbara J B Johnson; J Stephen Dumler
Journal:  Diagn Microbiol Infect Dis       Date:  2012-10-11       Impact factor: 2.803

7.  Lyme disease in children in southeastern Connecticut. Pediatric Lyme Disease Study Group.

Authors:  M A Gerber; E D Shapiro; G S Burke; V J Parcells; G L Bell
Journal:  N Engl J Med       Date:  1996-10-24       Impact factor: 91.245

8.  Neuroactive kynurenines in Lyme borreliosis.

Authors:  J J Halperin; M P Heyes
Journal:  Neurology       Date:  1992-01       Impact factor: 9.910

9.  Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  J J Halperin; E D Shapiro; E Logigian; A L Belman; L Dotevall; G P Wormser; L Krupp; G Gronseth; C T Bever
Journal:  Neurology       Date:  2007-05-23       Impact factor: 9.910

10.  Persistence of Borrelia burgdorferi in rhesus macaques following antibiotic treatment of disseminated infection.

Authors:  Monica E Embers; Stephen W Barthold; Juan T Borda; Lisa Bowers; Lara Doyle; Emir Hodzic; Mary B Jacobs; Nicole R Hasenkampf; Dale S Martin; Sukanya Narasimhan; Kathrine M Phillippi-Falkenstein; Jeanette E Purcell; Marion S Ratterree; Mario T Philipp
Journal:  PLoS One       Date:  2012-01-11       Impact factor: 3.240

View more
  5 in total

Review 1.  A Clinical Approach to the Differential Diagnosis of Multiple Sclerosis.

Authors:  Michel Toledano; Brian G Weinshenker; Andrew J Solomon
Journal:  Curr Neurol Neurosci Rep       Date:  2015-08       Impact factor: 6.030

2.  Atypical presentation of Lyme neuroborreliosis related meningitis and radiculitis.

Authors:  Iman Dabiri; Nicholas Calvo; Feryal Nauman; Mahsa Pahlavanzadeh; Ahmet Z Burakgazi
Journal:  Neurol Int       Date:  2019-12-02

3.  Acute lyme disease IgG N-linked glycans contrast the canonical inflammatory signature.

Authors:  Benjamin Samuel Haslund-Gourley; Stéphane Grauzam; Anand S Mehta; Brian Wigdahl; Mary Ann Comunale
Journal:  Front Immunol       Date:  2022-08-05       Impact factor: 8.786

4.  Lyme neuroborreliosis as a cause of sudden sensorineural hearing loss and facial palsy.

Authors:  Letizia Nitro; Barbara Martino; Emanuela Fuccillo; Giovanni Felisati; Alberto Maria Saibene
Journal:  Clin Case Rep       Date:  2022-10-11

5.  [Severe epigastric pain in a 59-year-old patient].

Authors:  S Welland; C Janssen; K I Ringe; G Höglinger; M P Manns; Ingmar Mederacke
Journal:  Internist (Berl)       Date:  2021-02       Impact factor: 0.743

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.